The company is also raising its full-year guidance to $14.9 billion in adjusted EBITDA, an 8.8% increase from its last projection. The U.S. is AstraZeneca’s largest market, generating 44% of its total revenue, according to its Q3 earnings presentation.

AstraZeneca plans a new investment of $2 billion in the U.S., one of the first major foreign companies to shift spending to the country after Donald Trump’s election win.The decision comes in response to the U.

AstraZeneca Plc raised its annual forecast, driven by strong demand for its blockbuster cancer drugs, and revealed a plan to invest $3.5 billion in the US business by the end of 2026.

AstraZeneca (NASDAQ:AZN) said it plans to spend $3.5B to expanding its research and manufacturing capabilities in the United States by the end of 2026. The U.K. drugmaker said the investment was part of its initiative to achieve $80B in total revenue by 2030.

AstraZeneca (GB:AZN) has released an update. AstraZeneca has announced a $3.5 billion investment in expanding its research and manufacturing